New Clinical Trial for MLD
GSK has just launched a Phase 3 clinical trial to study the efficacy of a cryopreserved formulation of their gene therapy, i.e. freezing the modified cells before transfusion.
Recruiting of pre-symptomatic late infantile and early juvenile patients will start immediately.
This study still requires patients to travel to Milano, Italy for their transplant – similar to how previous patients have accessed the San Rafaelle gene therapy.
Laying The Groundwork for Sites in Other Countries
Most notable is that this trial lays the groundwork for patients to eventually access the gene therapy in a local medical center outside of Italy. Their cells will still be genetically modified in Italy – the cryopreservation allows for international transport of the modified cells. In the USA, the next step would be a New Drug Application (NDA) to seek approval for offering the gene therapy in the USA.
Inclusion criteria can be found here. We are happy to discuss this trial and inclusion criteria with any of you tat think you may be eligible. We know the Principal Investigator in Italy well and can help you with the referral process to assess eligibility.
For those of you wishing to dig little deeper, here’s a good article about gene therapy cyropreservation – in general, not necessary reflecting the the GSK/San Rafaelle flow or specific issues.
Please subscribe to this blog (button in the upper right part of this page – if you are reading this in email you are already subscribed!) to be kept up to date on this new Clinical Trial.
2 replies on “GSK Launches Phase 3 Cryopreserved Gene Therapy Clinical Trial”
Do the patients have to be pre-symptomatic? My daughter was diagnosed in July 2010. She is very symptomatic. We have not given up hope on future treatments.
Yes, pre-symptomatic late infantiles.